AURX
insider transactionsNuo Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
No open-market buys or sells this period. The trades below are grants, option exercises and gifts, which carry no market price.
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
Transactions · 30d
No open-market buys or sells in this period — showing all activity (grants, exercises & gifts).
-
Grant·A
CEO/CFO
$14.5K
13.2K sh · $1.10
Own +1%
-
Grant·A
Director, 10% Owner
$63.4K
42.3K sh · $1.50 avg · 3 lots
Own New
-
Other·D
Director, 10% Owner
$66.4K
44.3K sh · $1.50 avg · 2 lots
Own -100%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 5, 2026 | JORDEN DAVID EMERSON KEY | Grant A | 13.2K | $14.5K |
| May 29, 2026 | Pittman Scott M. | Grant A | 42.3K3 lots | $63.4K |
| May 29, 2026 | Pittman Scott M. | Other D | 44.3K2 lots | $66.4K |
Buy Sell Non-market (grant · exercise · gift)
About AURX insider trading
This page tracks insider transactions for Nuo Therapeutics, Inc. (AURX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.